{"url_path":"/sec/gyre/8-k/2026-06-02/item-7-01","section_key":"item-7-01","section_title":"Item 7.01 Regulation FD Disclosure.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-02","source_url":"https://www.sec.gov/Archives/edgar/data/1124105/0001140361-26-023625-index.html","accession_number":"0001140361-26-023625","cik":"0001124105","ticker":"GYRE","issuer_name":"GYRE THERAPEUTICS, INC.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1124105/0001140361-26-023625-index.html","primary_entity_key":"0001124105","primary_entity_name":"GYRE THERAPEUTICS, INC."},"word_count":126,"has_tables":true,"body_markdown":"Item 7.01\n\nRegulation FD Disclosure.\n\n \n\nOn June 1, 2026, Gyre Therapeutics, Inc. (the “Company”) made available an updated corporate presentation on the Company’s website.\n\n \n\nA copy of the corporate presentation is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein. The exhibit\nfurnished under Item 7.01 of this Current Report on Form 8-K shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that\nsection, nor shall it be deemed incorporated by reference in any filing under the Exchange Act or the Securities Act of 1933, as amended, regardless of any general incorporation language in such filing."}